05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£23,469,435 |
Nicolas Loebel |
3,538,991 |
£531,354 |
Junaid Bajwa |
1,193,697 |
£179,225 |
Jean Duvall |
1,163,529 |
£174,696 |
Jean Charest |
353,356 |
£53,054 |
Simon Sinclair |
256,327 |
£38,486 |
Carolyn Cross |
119,258,222 |
£17,905,770 |
M&G Plc |
67,254,901 |
£10,097,843 |
Robert Cross |
37,772,652 |
£5,671,294 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,268,040 |
CRUX Asset Management |
9,298,090 |
£1,396,042 |
Chelverton Asset Management |
7,957,311 |
£1,194,733 |
10:02 |
20,000 @ 15.25p |
09:16 |
25,000 @ 15.12p |
08:47 |
13,206 @ 15.12p |
08:33 |
19 @ 15.50p |
08:00 |
18,547 @ 15.12p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research